Jesse Keller

672 total citations
21 papers, 476 citations indexed

About

Jesse Keller is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Jesse Keller has authored 21 papers receiving a total of 476 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 8 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Jesse Keller's work include Multiple Myeloma Research and Treatments (11 papers), Protein Degradation and Inhibitors (4 papers) and Peptidase Inhibition and Analysis (4 papers). Jesse Keller is often cited by papers focused on Multiple Myeloma Research and Treatments (11 papers), Protein Degradation and Inhibitors (4 papers) and Peptidase Inhibition and Analysis (4 papers). Jesse Keller collaborates with scholars based in United States and Canada. Jesse Keller's co-authors include Kenneth R. Carson, Kristen M. Sanfilippo, Suhong Luo, Brian F. Gage, Tzu‐Fei Wang, Nicole M. Kuderer, Michael Slade, Tanya M. Wildes, Ravi Vij and Mark A. Fiala and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Jesse Keller

20 papers receiving 473 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jesse Keller United States	10	232	193	98	82	81	21	476
Irina Zaidman Israel	13	146 0.6×	73 0.4×	25 0.3×	97 1.2×	50 0.6×	47	438
B. Dörken Germany	7	108 0.5×	98 0.5×	45 0.5×	48 0.6×	65 0.8×	22	384
G. А. Novichkova Russia	11	238 1.0×	87 0.5×	13 0.1×	79 1.0×	89 1.1×	147	457
Tomiko Ryu Japan	8	162 0.7×	54 0.3×	22 0.2×	42 0.5×	37 0.5×	27	323
Patrick Ellsworth United States	10	141 0.6×	53 0.3×	17 0.2×	70 0.9×	117 1.4×	20	396
Renaud Lavend’homme Belgium	14	648 2.8×	80 0.4×	29 0.3×	221 2.7×	134 1.7×	32	852
J. M. Trujillo United States	9	129 0.6×	96 0.5×	29 0.3×	113 1.4×	30 0.4×	14	329
Jessica Hochberg United States	14	92 0.4×	279 1.4×	13 0.1×	76 0.9×	58 0.7×	43	552
Maria-Elena Cabezudo Spain	11	173 0.7×	93 0.5×	31 0.3×	51 0.6×	88 1.1×	23	337
Zohra Ahmadi Australia	8	222 1.0×	23 0.1×	63 0.6×	136 1.7×	21 0.3×	17	588

Countries citing papers authored by Jesse Keller

Since Specialization

Citations

This map shows the geographic impact of Jesse Keller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jesse Keller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jesse Keller more than expected).

Fields of papers citing papers by Jesse Keller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jesse Keller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jesse Keller. The network helps show where Jesse Keller may publish in the future.

Co-authorship network of co-authors of Jesse Keller

This figure shows the co-authorship network connecting the top 25 collaborators of Jesse Keller. A scholar is included among the top collaborators of Jesse Keller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jesse Keller. Jesse Keller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sanfilippo, Kristen M., Kenneth R. Carson, Tzu‐Fei Wang, et al.. (2022). Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma. Research and Practice in Thrombosis and Haemostasis. 6(1). e12634–e12634. 22 indexed citations

Hoque, Shamia, Brian Chen, Martin W. Schoen, et al.. (2020). End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia. PLoS ONE. 15(6). e0234541–e0234541. 3 indexed citations

Sanfilippo, Kristen M., Suhong Luo, Tzu‐Fei Wang, et al.. (2019). Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. American Journal of Hematology. 94(11). 1176–1184. 112 indexed citations

Compton, Leigh A., et al.. (2019). Disseminated blastomycosis in a patient on pembrolizumab for metastatic melanoma. JAAD Case Reports. 5(7). 580–581. 3 indexed citations

Pastula, Daniel M., Amy J. Lambert, J. Erin Staples, et al.. (2018). Heartland Virus and Hemophagocytic Lymphohistiocytosis in Immunocompromised Patient, Missouri, USA. Emerging infectious diseases. 24(5). 893–897. 19 indexed citations

Romee, Rizwan, Michael Slade, D. Phelan, et al.. (2017). Untreated donor specific antibodies against HLA are associated with poor outcomes in peripheral blood haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation. 52(6). 898–901. 14 indexed citations

Acharya, Sahaja, D. Mullen, Deshan Yang, et al.. (2017). Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents. Advances in Radiation Oncology. 2(4). 572–580. 55 indexed citations

Fiala, Mark A., Jesse Keller, Camille N. Abboud, et al.. (2017). A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone [CDD] for Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 17(1). e56–e56. 1 indexed citations

Abboud, Ramzi, Jesse Keller, Michael Slade, et al.. (2016). Severe Cytokine-Release Syndrome after T Cell–Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti–IL-6 Therapy Is Safe and Well Tolerated. Biology of Blood and Marrow Transplantation. 22(10). 1851–1860. 104 indexed citations

10.

Sanfilippo, Kristen M., Jesse Keller, Brian F. Gage, et al.. (2016). Statins Are Associated With Reduced Mortality in Multiple Myeloma. Journal of Clinical Oncology. 34(33). 4008–4014. 68 indexed citations

11.

Fiala, Mark A., Jesse Keller, Camille N. Abboud, et al.. (2016). A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for Relapsed or Refractory Multiple Myeloma. Blood. 128(22). 3329–3329. 2 indexed citations

12.

Krishnan, Amrita, Ravi Vij, Jesse Keller, Binod Dhakal, & Parameswaran Hari. (2016). Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy. American Society of Clinical Oncology Educational Book. 36. 210–221. 4 indexed citations

13.

Edwin, Natasha, Jesse Keller, Suhong Luo, et al.. (2016). Application of a Validated Predictive Model for Venous Thromboembolism in Cancer to Patients with Multiple Myeloma. Blood. 128(22). 534–534. 1 indexed citations

14.

Zhou, Amy, Manik Amin, Kathryn J. Fowler, et al.. (2015). Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary) Primary Liver Carcinoma. Journal of the National Comprehensive Cancer Network. 13(12). 1468–1473. 9 indexed citations

15.

Vij, Ravi, et al.. (2015). Targeted treatments for multiple myeloma: specific role of carfilzomib. Pharmacogenomics and Personalized Medicine. 8. 23–23. 18 indexed citations

16.

Keller, Jesse, Kristen M. Sanfilippo, Suhong Luo, Brian F. Gage, & Kenneth R. Carson. (2015). Metformin Therapy and Survival in Multiple Myeloma Among US Veterans with Diabetes Mellitus. Blood. 126(23). 4502–4502.

17.

Keller, Jesse, Mark A. Fiala, Michael Slade, et al.. (2015). Presenting Characteristics and Symptom Burden of Newly Diagnosed Older Multiple Myeloma Patients in the Commpass Study. Blood. 126(23). 3307–3307. 1 indexed citations

18.

Keller, Jesse & Kenneth R. Carson. (2015). Risk-adapted strategies for the treatment of Hodgkin lymphoma. Expert Opinion on Drug Safety. 14(10). 1519–1530. 1 indexed citations

19.

Fiala, Mark A., Jesse Keller, Keith Stockerl‐Goldstein, et al.. (2014). Treatment Advances for Multiple Myeloma Have Disproportionally Benefited Patients Who Are Young, White, and Have Higher Socioeconomic Status. Blood. 124(21). 555–555. 4 indexed citations

20.

Devine, Steve, RB Geller, Liming Lin, et al.. (1997). The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.. PubMed. 3(1). 25–33. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact